NEW AND NEWLY REVISED FUNDING OPPORTUNITIES:

**Leukemia & Lymphoma Society** offers **The New Idea Award**, designed to identify novel research strategies with a potential for high impact on blood cancer. Specifically, this program supports the initial exploration of untested but potentially transformative ideas that challenge our knowledge of blood cancer or the manner in which we approach diagnosis or treatment. Competitive proposals will describe ideas that take the investigator’s research in a substantially new direction, and thus preliminary data is not required. Grants will be awarded in an amount of up to $75,000 for a one-year period. **Letter of Intent Deadline (required) is July 31, 2017** with full application (by invitation) due November 30.

**Society of Gynecologic Oncology (SGO)** and **Foundation for Women's Cancer (FWC)** offers one-year **Research Grant and Prizes** ranging from $1,000 to $65,000 for early career/emerging in field and mid-career/established in field researchers engaged in in gynecologic cancer biomedical, behavioral or clinical research. **Applications are due August 25, 2017.**

**Leukemia & Lymphoma Society** offers **Career Development Program – Scholar**, a five-year award at up to $110,000 per year, providing the opportunity to take part in basic, clinical or translational research to help understand and treat hematologic malignancies and relevant premalignant conditions. This program is intended to further develop the independent research careers of highly qualified investigators, not to support well-established or senior investigators. Applicants must have been appointed to their independent, tenure-track faculty position on or more recent than January 1, 2017. **Deadline for Letter of Intent (required) is September 1, 2017 with abstract (by invitation) due September 15, 2017 and final application due October 3, 2017.**

**Leukemia & Lymphoma Society** offers **Career Development Program - Scholar in Clinical Research** providing up to $125,000 per year for up to five-years for basic, clinical or translational research to help understand and treat hematologic malignancies and relevant premalignant conditions. The award is intended to further develop the independent research careers of highly qualified investigators, not to support well-established or senior investigators. Applicants must be a highly qualified investigator who holds an independent faculty-level appointment and is conducting original, independent applied research, often involving early-stage clinical trials that will advance the prevention, diagnosis or treatment of hematologic malignancies. Applicants are expected to have concomitant support for your research from another source or agency. Eligibility has expanded to include any permanent, independent clinical faculty who are not on a laboratory-based, tenure-track career path. **Deadline for Letter of Intent (required) is September 1, 2017 with abstract (by invitation) due September 15, 2017 and final application due October 3, 2017.**

**The Lymphoma Research Foundation (LRF)** offers multiple funding opportunities at levels ranging from $100,000 to $250,000 over multi-year periods. **Applications for all programs are due by 5:00 pm EST September 6, 2017:**

- **Young Investigator Grants**
  - Clinical Investigator Career Development Award (CDA) RFP
  - Postdoctoral Fellowship Grant RFP
  - Lymphoma Clinical Research Mentoring Program (LCRMP) RFP
- **Disease Focus Area Grants**
  - Adolescent/Young Adult (AYA) Lymphoma Correlative Studies Grant RFP
  - Mantle Cell Lymphoma (MCL) Therapeutic Studies Grant RFP
- **Hope Funds for Cancer Research** offers $150,00 over three years through Postdoctoral Fellowships for highly innovative research projects that challenge the traditional paradigms of understanding the causes, mechanisms, progression, disease markers or risk factors of the most difficult-to-treat cancers, including pancreatic, lung, liver, sarcomas, esophageal, brain, gastric, bone and ovarian cancers; and rare leukemias, lymphomas and MDS. **Deadline for Letter of Intent (required) is September 15, 2017 with final application (by invitation) due January 14, 2018.**
Conquer Cancer Foundation of ASCO offers a three-year, $200,000 Career Development Award (CDA) that provides funding to physician investigators who are in the first to third year of a full-time primary faculty appointment with a demonstrated ability to undertake independent investigator-initiated clinical research. The cancer research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Proposals with a predominant focus on in vitro or animal studies (even if clinically relevant) are not allowed.

Applications are due September 21, 2017.

Leukemia & Lymphoma Society offers Specialized Center of Research Program offering up to $1,000,000 per year for up to five years to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hemotological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects. Deadline for Letter of Intent (required) is September 22, 2017 with full application (by invitation) due March 3, 2018.

National Heart, Lung, and Blood Institute/NIH/DHHS RFA-HL-18-021--Consortium Linking Oncology with Thrombosis (CLOT) (U01) provides up to $500,000 per year for up to five-years to encourage studies in selected cancer types that expand mechanistic investigation into the intersection between cancer and thrombotic pathways; and apply mechanistic insights towards the identification and development of biomarkers of thrombotic risk or cancer progression and new strategies for preventing or treating the deleterious interplay between cancer, cancer therapy, and hemostasis/thrombosis. Optional Letter of Intent deadline is September 23, 2017, with full applications due October 23, 2017 and January 8, 2018.

National Cancer Institute (NCI)/NIH/DHHS Gene Fusions in Pediatric Sarcomas PA-16-251 R01 and PA-16-252 R21 seeks research grant applications to investigate the molecular mechanisms by which oncogenic fusion genes and their gene products contribute to pediatric sarcoma initiation, progression, and metastasis. Better understanding of the molecular pathways activated by chromosomal translocations in pediatric sarcomas, and their relationship to oncogenesis and tumor progression, can elucidate mechanisms of cancer pathogenesis and potentially lead to novel therapeutics. Next Deadlines: October 5, 2017 (R01) and October 16, 2017 (R21) with subsequent deadlines to February 2019.

American Cancer Society, Inc. announces several research funding opportunities, all with Application Deadlines of October 16, 2017.

Research Scholar Grants to support investigator-initiated projects across the cancer research continuum. Awards are for up to four years and for up to $165,000 per year (direct costs), plus 20% allowable indirect costs. Independent investigators in the first six years of an independent research career or faculty appointment are eligible to apply.

Mentored Research Scholar Grants of up to $135,000 per year over up to five-years for for mentored research and training to full-time junior faculty, typically within the initial four years of their first independent appointment. The goal is for these beginning investigators to become independent researchers as either clinician scientists or cancer control and prevention researchers. A maximum of $10,000 per year for the mentor(s) (regardless of the number of mentors) is included in the $135,000.

Postdoctoral Fellowships totaling $113,500 over three-years that are designed to support a program of research training and study to enable a new investigator to qualify for an independent career in cancer research. The Peer Review Committee reviewing the application will consider whether the fellowship broadens the applicant’s research training and experience.
Cancer Control Career Development Awards for Primary Care Physicians of $100,000 per year over three-years to support Primary Care Physicians in supervised programs to develop clinical and teaching expertise and the capacity to perform independent research or educational innovation in cancer control.

Research Scholar Grant in the Role of Healthcare and Insurance in Improving Outcomes in Cancer Prevention, Early Detection and Treatment for research that evaluates the impact of the many changes now occurring in the health care system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives, for example the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by health care systems, insurers, payers, communities, practices, and patients. The awards are for up to four years and for up to $165,000 per year (direct costs), plus 20% allowable indirect costs. Independent investigators in the first six years of an independent research career or faculty appointment are eligible to apply.

Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families supports two-year research projects at up to $60,000 per year for clinician investigators conducting patient-oriented research in palliative care of cancer patients and their families. These grants will generate the pilot data necessary to maximize an investigator’s chances of competing successfully for larger grants.

UPCOMING DEADLINES:

July 2017

Breast Cancer Alliance, Inc. invites clinical doctors and research scientists whose primary focus is breast cancer research and who are in the early stages of their career (no more than four years from completion of training), to apply for funding for the Young Investigator Grant, a two-year award for a total of $125,000. Application deadline is July 21, 2017.

Patient-Centered Outcomes Research Institute (PCORI) Symptom Management for Patients with Advanced Illness - Cycle 2 2017 supports projects of up to 3 years duration at up to $2,000,000 for clinical studies that compare the effectiveness of evidence-based treatments for relief of common symptoms experienced by patients with advanced illness. The goal of this initiative is to support patient- and caregiver-centered comparative clinical effectiveness research (CER) to generate important findings that will aid clinical decision making for symptom management. The proposed interventions must include an evidence-based pharmacological treatment and one or more appropriate pharmacological or non-pharmacological interventions that reflect the decision making and choices in contemporary clinical practice. This PFA is specifically focused on the following symptoms: Pain, Fatigue, Dyspnea, Insomnia, Anorexia/cachexia, Nausea/vomiting, Depression and/or anxiety. Letter of Intent deadline is July 25, 2017.

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs (CDMRP): Prostate Cancer Research (PCRP) - Physician Research Award up to $520,000 to support a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. Applicants should be Physicians with clinical duties and/or responsibilities who, at the application submission deadline, are either in the last year of an accredited graduate medical education program as a resident or fellow, or within 3 years of having initiated an appointment as an Instructor, Assistant Professor, or equivalent. Letter of intent (required) is due July 27, 2017.

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs (CDMRP): Prostate Cancer Research (PCRP) - Early Investigator Research Award up to $200,000 to support prostate cancer-focused research opportunities for individuals in the early stages of their careers, under the guidance of a designated Mentor. Letter of intent (required) is due July 27, 2017.
Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs (CDMRP): Lung Cancer Research (LCRP) - Concept Award provides up to $100,000 to support the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to lung cancer. The Concept Award is not intended to support an incremental progression of an already established research project but, instead, allows Principal Investigators (PIs) the opportunity to pursue serendipitous observations. This award mechanism supports high-risk studies that have the potential to reveal entirely new avenues for investigation. Applications must describe how the new idea will enhance the existing knowledge of lung cancer or develop an innovative and novel course of investigation. Submissions from and partnerships with investigators at military treatment facilities, military labs, and Department of Veterans Affairs (VA) medical centers and research laboratories are strongly encouraged. Research completed through a Concept Award may generate sufficient preliminary data to enable the PI to prepare an application for future research. Presentation of preliminary data is not consistent with the intent of the Concept Award mechanism. While the inclusion of preliminary data is not prohibited, the strength of the application should not rely on preliminary data. **Pre-application deadline July 27, 2017**

**AUGUST 2017**

The **International Myeloma Foundation** Brian D. Novis Research Awards for research into multiple myeloma and related disorders **Junior Grants** support new investigators at $50,000 and **Senior Grants** support established investigators at $80,000. **Application deadlines are August 1, 2017.**

**American Association for Cancer Research AACR Team Science Award** provides a $50,000 honorarium to an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention or treatment of cancer. **Nomination Deadline August 2, 2017**

**American Association for Cancer Research AACR-CRI Lloyd J. Old Award in Cancer Immunology** – provides a $10,000 honorarium to recognize an active scientist whose outstanding and innovative research in cancer immunology has had a far-reaching impact on the cancer field. **Nomination Deadline August 2, 2017**

**American Association for Cancer Research (AGA) - R. Robert & Sally Funderburg Research Award in Gastric Cancer** provides $50,000 per year over two years to support an established investigator in the field of gastric biology whose research will enhance the fundamental understanding of gastric cancer pathobiology to ultimately prevent or develop a cure for the disease. **Application deadline is August 4, 2017.**

**Meso Foundation**-sponsored **Grants for Mesothelioma Research** are two-year grants for up to $50,000 per year supporting strategies for early detection and prevention of mesothelioma; Definition of targetable differences between normal and transformed mesothelium and development of novel strategies for treatment taking advantage of these targets; Determination of clinical/molecular determinants for prognosis; and Therapeutic intervention, including but not limited to immune response targeted therapy, novel chemotherapeutic compounds, and novel radiation or surgical techniques. **Applications are due August 5, 2017.**

**American Association for Cancer Research Pezcoller Foundation-AACR International Award for Cancer Research** Provides a €75,000 honorarium to annually recognize a scientist of international renown who has made a major scientific discovery in basic cancer research OR who has made significant contributions to translational cancer research; who continues to be active in cancer research and has a record of recent, noteworthy publications; and whose ongoing work holds promise for continued substantive contributions to progress in the field of cancer. **Nomination Deadline August 9, 2017**
American Society of Cytopathology Foundation (ASC Foundation) offers a number of grants & scholarships ranging from $2,000 travel grants to $10,000 Patient Advocacy grants to $50,000 Early & Mid-Career investigator grants. Application deadline for all programs is August 15, 2017.

American Association for Cancer Research AACR-American Cancer Society Award for Research Excellence in Cancer Epidemiology and Prevention provides a $5,000 honorarium in recognition of outstanding research accomplishments in the fields of cancer epidemiology, biomarkers, and prevention. Nomination Deadline August 16, 2017

American Association for Cancer Research AACR Princess Takamatsu Memorial Lectureship provides a $10,000 honorarium in recognition of an individual scientist whose novel and significant work has had or may have a far-reaching impact on the detection, diagnosis, treatment, or prevention of cancer, and who embodies the dedication of the Princess to multinational collaborations. The recipient of the Twelfth Annual Lectureship will present a major award lecture during the AACR Annual Meeting 2018 in Chicago, IL, USA (April 14-18, 2018). Nomination Deadline August 16, 2017

Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) Nurse Researcher Discovery Grant provides up to $100,000 over two years to encourage nursing research at various levels of practice. The Discovery Grant category aims to support independent and experienced nurse researchers and must include plans to disseminate and share findings to improve nursing care for children with cancer. Deadlines is August 21, 2017.

American Association for Cancer Research AACR Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research provides a $10,000 honorarium to an individual whose leadership and extraordinary achievements in cancer research or in support of cancer research have made a major impact on the field. Such achievements include contributions to the acceleration of progress in cancer research, raising national or international awareness of cancer research, or other demonstrations of a sustained commitment to the conquest of cancer. Nomination Deadline August 23, 2017

American Association for Cancer Research AACR Award for Lifetime Achievement in Cancer Research honors an individual who has made significant fundamental contributions to cancer research, either through a single scientific discovery or a body of work. These contributions, whether they have been in research, leadership or mentorship, must have had a lasting impact on the cancer field and must have demonstrated a lifetime commitment to progress against cancer. Nomination Deadline August 23, 2017

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs (CDMRP): Prostate Cancer Research (PCRP) - Clinical Consortium Award up to $3,600,000 to develop and enhance collaborations and resources necessary for a network of organizations to rapidly execute Phase II or Phase II-linked Phase I (Phase I/II) prostate cancer clinical trials. Letter of intent (required) is due August 24, 2017.

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs (CDMRP): Prostate Cancer Research (PCRP) - Prostate Cancer Pathology Resource Network Award provides $5,800,000 over three years ($1,900,000 in the first year) for infrastructure support for the development and maintenance of a prostate cancer biorepository. Letter of intent (required) is due August 24, 2017.

Syopajarjestot / Cancer Society of Finland offers grants ranging from €3-5,000 for dissertation grants to €450,000 for three-year major grants, with an emphasis on breast cancer. While priority is given to research conducted in Finland, there are no geographic restrictions on these awards. Application deadlines for all programs is 26 August 26, 2017.

AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research provides a $10,000 honorarium to a worthy cancer researcher who has conducted highly meritorious laboratory, translational, or clinical cancer research.
anywhere in the world at a relatively early state in his or her career. Candidates must have not yet reached 46 years of age at the time of the presentation of the award. **Deadline for nominations is August 30, 2017.**

**Bayer HealthCare Grants4Targets Initiative - Pharmaceuticals** offers support grants (€ 5,000 - €10,000), and focus grants (€ 10,000 - €125,000) for researchers investigating novel drug targets in oncology to promote innovative therapeutic ideas from basic research into novel drugs. Oncology grants focus on tumor cell proliferation, survival signaling, transcription and chromatin modulation, cell cycle regulation, tumor metabolism, hypoxia, cancer immunotherapy and Antibody Drug Conjugates (ADC). **The next deadline is August 31, 2017.**

**SEPTEMBER 2017**

**American Association for Cancer Research AACR- Stand Up To Cancer (SU2C) Dream Team Translational Research Grant** provides up to $10,000,000 over a 3-year grant term to fund a translational cancer research project that will address critical problems in patient care, including prevention strategies for those at risk, and deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, collaborative Dream Team of expert investigators. The ideas may focus on particular organ sites, patient populations (such as pediatrics) or on innovative methods of treatment. Projects must be designed to accelerate the application of new preventive, diagnostic or therapeutic approaches to the clinic (i.e., lead to patient involvement within 2-3 years from the beginning of the grant). Proposals for Dream Team research projects must present plans indicating how the work will be translated into the clinic. The ideas should be based on perceived opportunities for success as well as high-priority areas with a critical need for rapid progress beyond current medical care. **Mandatory Letter of intent Deadline is September 5, 2017; Full Application Deadline is January 16, 2018**

**National Cancer Institute (NCI)/NIH/DHHS** Leveraging Population-based Cancer Registry Data to Study Health Disparities **PA-17-289 R01** and **PA-17-288 R21** award mechanisms support efficient use of existing cancer registry infrastructure by augmenting data already collected with additional information needed to understand health disparities among people diagnosed with cancer. **Earliest submission dates are September 5, 2017 (R01) and September 16, 2017 (R21)** with subsequent deadlines through September 2020.

**National Cancer Institute (NCI)/NIH/DHHS PA-16-175 Exploratory Grants in Cancer Epidemiology and Genomics Research (R21)** supports research on cancer epidemiology, genomics, and risk assessment. By promoting the early and conceptual stages of research efforts on novel scientific ideas that have the potential to substantially advance cancer research, such as improving epidemiologic study data collection; validating measurement of exposures in body fluids and tissues; applying epigenetic or metabolomic approaches to cancer epidemiology research; developing and applying novel strategies for discovery of risk variants for rare cancers; understanding the population genetic architecture of cancer in understudied populations; or validating methods to extract, collect, and synthesize clinical data via electronic medical records for use in observational studies of cancer patients and survivors. **Next deadline is September 7, 2017** with subsequent deadlines until May 9, 2019.

**American Association for Cancer Research Joseph H. Burchenal Memorial Award for Outstanding Achievement in Clinical Cancer Research** provides a $10,000 honorarium to recognize outstanding achievements in clinical cancer research. **Nomination Deadline September 6, 2017**

The **Lymphoma Research Foundation** announces:

- **Young Investigator Grants - Postdoctoral Fellowships**: $105,000 over two years for research on etiology, immunology, genetics, therapies and transplantation in Hodgkin and/or non-Hodgkin lymphoma. Applicants must have completed at least two years but not more than five years of fellowship or postdoctoral work at the start of their award period. **Deadline for applications is September 6, 2017.**

- **Clinical Investigator Career Development Awards**: $225,000 over three years for advanced fellow or junior faculty physician investigators developing new lymphoma therapies and diagnostic tools. Eligible investigators
must have no greater than five years of experience beyond completion of their fellowship or post-doctoral training and must be clinical physicians in an ACGME accredited specialty (hematology/oncology, pathology, dermatology, or radiation oncology). **Deadline for applications is September 6, 2017.**

National Cancer Institute (NCI) & National Institute on Aging (NIA) **The Role of Mobile Genetic Elements in Cancer**

PAR-16-226 (R21) & PAR-16-227 (R01) support projects that investigate mechanisms regulating the expression and activity of mobile genetic elements, including long terminal repeat (LTR) and non-LTR retroelements, in cancer. **Next deadline is September 7, 2017** with subsequent deadlines to September 7, 2019

**CONquer canCER Now Award** is a $60,000 grant given to young and innovative cancer researchers focused on cancer genetics, cancer biology and cancer immunology. Approximately 20 researchers receive a $60,000 Conquer Cancer Now Award per year for the two-year grant cycle. Proposals must be hypothesis-driven and centered on cancer genetics, cancer biology, or cancer immunology. Concern will not fund clinical trials, cancer epidemiology, or behavioral studies. The **Concern Foundation** is now accepting LOI’s through **September 7th, 2017.**

National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS - PAR-16-242 **Bioengineering Research Grants (BRG) (R01)** supports collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical or translational science. **Next deadline is September 7, 2017** with subsequent deadlines until September 7, 2019.

National Institute on Aging/NIH/DHHS - PAR-15-281 **Multidisciplinary Studies of HIV/AIDS and Aging (R03)** and PAR-15-282 **Multidisciplinary Studies of HIV/AIDS and Aging (R21)** support research into HIV infection, HIV-associated conditions, HIV treatment, and/or biobehavioral or social factors associated with HIV/AIDS in the context of aging and/or in older adults. Research approaches of interest include clinical translational, observational, and intervention studies in domestic and international settings. **Next deadline is September 7, 2017** with subsequent deadlines until September 7, 2019.

National Cancer Institute (NCI)/NIH/DHHS – PAR-16-258 **Mechanisms of Cancer and Treatment-related Symptoms and Toxicities (R21)** supports innovative pilot projects or feasibility studies to stimulate research aimed to better understand the complex interaction of biological, cognitive, behavioral, and sociocultural factors that contribute to cancer and treatment related symptoms and toxicities throughout the cancer care trajectory. Data from the preliminary studies would be used to validate and extend the findings in larger cohort studies and/or test novel, mechanistically-driven interventions via the R01 funding mechanism. Of particular interest is to gain new insights about these factors, either alone or in combination, in minority, underserved, the elderly, and pediatric and young adult populations. Specifically, the FOA aims to identify, describe, and quantify these factors associated with acute and chronic cancer and treatment related symptoms and toxicities. **Next deadline is September 7, 2017** with subsequent deadlines until September 7, 2018.

National Cancer Institute (NCI)/NIH/DHHS – PAR-16-284 **Cancer Prevention, Control, Behavioral Sciences, and Population Sciences Career Development Award (K07)** supports the career development of junior investigators with research or health professional doctoral degrees who want to become cancer-focused academic researchers in cancer prevention, cancer control, or the behavioral or population sciences. **Next deadline is September 7, 2017** with subsequent deadlines of October 12, 2017 and January 7, 2018.

National Cancer Institute (NCI) & National Institute of Biomedical Imaging and Bioengineering (NIBIB) /NIH/DHHS PAR-15-075 **Academic-Industrial Partnerships for Translation of Technologies for Cancer Diagnosis and Treatment**
(R01) supports research partnerships formed by academic and industrial investigators, to accelerate the translation of technologies, methods, assays or devices, and/or systems for preclinical or clinical molecular diagnosis or in vitro imaging that are designed to solve a targeted cancer problem. Next deadline is September 7, 2017 with subsequent deadlines of October 8, 2017 and January 8, 2018 after which the program expires.

National Cancer Institute (NCI)/NIH/DHHS PA-15-127 Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01) supports interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies. Next deadline is September 7, 2017 with subsequent deadlines until May 7, 2018.

National Cancer Institute (NCI)/NIH/DHHS PA-15-135 Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) supports basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics. Next deadline is September 7, 2017 with subsequent deadlines until May 7, 2018.

National Cancer Institute (NCI)/NIH/DHHS PAR-16-278 Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21) supports innovative interventions that improve cancer-related health behaviors across diverse racial/ethnic populations. Specifically, this FOA is intended to stimulate research aimed at 1) testing new theories and conceptual frameworks; 2) developing and evaluating novel strategies to improve cancer-related health behaviors; 3) investigating multi-level and multi-behavioral approaches; and 4) utilizing innovative research designs, methodologies, and technologies. The cancer-related health behaviors to be targeted are diet, obesity, physical activity and sedentary behavior, smoking, sleep and circadian dysfunction, alcohol use, and/or adherence to cancer-related medical regimens. Research can involve any aspect of the cancer continuum and any phase of the translational spectrum. Next deadline is September 7, 2017 with subsequent deadlines until January 7, 2019.

Gilead Sciences Research Scholars Program in Hematology/Oncology provides $65,000 per year over two years for junior faculty researchers conducting innovative scientific research that will advance knowledge in the field of hematology/oncology, with a focus on hematologic malignancies, and provide support for research career development. Application deadline is September 8, 2017.

National Cancer Institute (NCI)/NIH/DHHS PAR-16-380 Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01) supports projects seeking to generate fundamental knowledge of affective processes with key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer control continuum. The FOA solicits applications that involve collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control. Optional Letter of Intent due September 10, 2017 with subsequent deadlines to October 2019.

American Association for Cancer Research AACR Award for Outstanding Achievement in Chemistry in Cancer Research provides a $10,000 honorarium in recognition of outstanding, novel and significant chemistry research, which has led to important contributions to the fields of basic cancer research, translational cancer research, cancer diagnosis, the prevention of cancer or the treatment of patients with cancer. Such research may include, but is not limited to, drug discovery and design; structural biology; proteomics, metabolomics and biological mass spectrometry; chemical aspects of carcinogenesis; imaging agents and radiotherapeutics; and chemical biology. Nomination Deadline September 13, 2017.
American Association for Cancer ResearchAACR-Minorities in Cancer Research Jane Cooke Wright Memorial Lectureship provides a $5,000 honorarium in recognition of an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of minority investigators in cancer research. **Nomination Deadline September 13, 2017**

American Association for Cancer ResearchAACR-Women in Cancer Research Charlotte Friend Memorial Lectureship provides a $5,000 honorarium in recognition of an outstanding female or male scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of women in science. **Nomination Deadline September 13, 2017**

Department of Defense (DOD)-U.S. Army Medical Research and Materiel Command (USAMRMC)-Office of Congressionally Directed Medical Research Programs (CDMRP): Lung Cancer Research (LCRP) - Career Development Award supports early-career, independent investigators to conduct impactful research under the mentorship of an experienced lung cancer researcher as an opportunity to obtain the funding, mentoring, and experience necessary for productive, independent careers at the forefront of lung cancer research. This award is intended to support impactful research projects with an emphasis on discovery. **Pre-application deadline September 13, 2017**

National Cancer Institute (NCI)/NIH/DHHS – PAR-16-276 Program to Assess the Rigor and Reproducibility of Exosome-Derived Analytes for Cancer Detection (R01) supports research projects that focus on innovative research in the isolation and characterization of exosomes and their cargo for discovery of predictive biomarkers for risk assessment, detection, diagnosis and prognosis of early cancer. This FOA will promote rigor and reproducibility research in both the isolation of exosomes as well as the computational analysis of the cargo carried in these vesicles. **Next deadlines are September 13, 2017 for optional LOI and October 13, 2017 for Application**, with subsequent deadlines until June 13, 2019.

Alex’s Lemonade Stand Foundation for Childhood Cancer (ALSF) Nurse Researcher Fellowship provides up to $100,000 over two years to support early career nurse researchers who will be guided in their projects by a mentor and their institution. The fellowship’s goal is to train PhD and Master’s level nurse researchers to initiate and lead a multi-site research project. **Deadline is September 25, 2017.**

TheBurroughs Wellcome Fund (BWF) announces a $25M initiative to help institutions address the shortage of physician-scientists by creating programs to increase the number of M.D.’s who enter careers in research. Toward this end, BWF’s Physician-Scientist Institutional Program is offering $30,000 to support five-month planning grants to 20-25 institutions to develop full proposals for awards of $2.5M each ($500,000 per year over five years). **Deadline for planning grant applications is 4pm September 28, 2017.** If awarded, full proposal would be due April 3, 2018.

**OCTOBER 2017**

Cancer Research Institute (CRI) CRI Irvington Postdoctoral Fellowship Program offers $175K over three years to fund and train young immunologists and cancer immunologists. The Institute seeks hypothesis-driven, mechanistic studies in both immunology and tumor immunology. Proposals must clearly state the potential of the proposed studies to directly impact our understanding of the immune system’s role in cancer risk, tumor initiation, progression, metastasis, host response to tumors and/or the treatment of cancer. **Deadlines are October 1, 2017 and April 1, 2018**

National Cancer Institute (NCI)/NIH/DHHS – Integration of Individual Residential Histories into Cancer Research PA-17-298 (R01) and PA-17-295 (R21) support investigation of the role of individual residential histories in cancer etiology and outcomes, and to encourage the development of complex analytical strategies in support of substantive investigation. This FOA is suitable for projects where proof-of-principle of the proposed technology or methodology has already been established and supportive preliminary data are available. **Next deadlines are October 5, 2017 (R01) and October 16, 2017 (R21), with subsequent deadlines into early 2019 for the R21 and mid 2020 for the R01.**
National Cancer Institute/NIH/DHHS PA-17-110 Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01) and PA-17-109 R21, funding research on interventions, based in healthcare settings, designed to reduce overscreening. Next Deadlines: October 5, 2017 (R01) and October 16, 2017 (R21) with subsequent deadlines through October 2019.

National Cancer Institute (NCI)/NIH/DHHS PAR-16-338 (R01), PAR-16-337 (R03), and PAR-16-336 (R21) Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake support research on how the healthcare delivery system enhances or inhibits the effectiveness of a provider's recommendation of the adolescent human papillomavirus (HPV) vaccine. Characteristics of the provider, parent/patient, and clinical setting, can all affect whether a provider makes a recommendation, and whether that recommendation results in uptake of the HPV vaccine. This research requires expertise in cancer prevention, adult and childhood behavior, immunization promotion, and healthcare delivery. Next deadline is October 5, 2017 for R01 and October 16, 2017 for R03 and R21, with subsequent deadlines into 2019.

National Cancer Institute (NCI)/NIH/DHHS Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions R01 PAR-16-202 & R21 PAR-16-201 provide support for innovative and promising intervention research designed to improve smoking cessation outcomes among socioeconomically disadvantaged populations. Deadlines are October 11, 2017 (R01 & R21) with subsequent deadlines through June 2019.

Fanconi Anemia Research Fund Research Grants provide $150,000 to $175,000 over two years to support research that focuses on the rapid discovery and development of therapies or strategies that treat, control, or cure Fanconi anemia, with a particular interest in interdisciplinary and translational research efforts that effectively address one or more of the following priorities: how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia; causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and strategies to prevent, treat, and cure these disorders; pathogenesis of Fanconi anemia-associated cancers, strategies for prevention, early detection, treatment and cure; practical and proactive management strategies that families and persons with Fanconi anemia can use to maintain a high quality of life; creation of shared resources, databases, and technologies for the international Fanconi anemia research community. Deadline for mandatory letter of intent is October 13, 2017.

National Cancer Institute (NCI)/NIH/DHHS - PAR-16-385 Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine (U24) supports development of research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve correlation of results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients’ malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource. Next deadline is October 18, 2017 with subsequent deadlines until June 14, 2018.

National Cancer Institute (NCI)/NIH/DHHS – PAR 15-334 Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21) supports the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum, including cancer biology, cancer treatment and diagnosis, cancer prevention, cancer control and
epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Initiative, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed informatics method or algorithm must have a clear rationale on why it is novel and how it will benefit the cancer research field. Next deadline is October 20, 2017 for optional LOI and November 20, 2017 for full applications, with subsequent deadlines of May 14, 2018 and June 14, 2018.

**NOVEMBER 2017**

**National Cancer Institute (NCI)/NIH/DHHS – PAR-16-044 Image-guided Drug Delivery (R01)** supports innovative research projects that are focused on image-guided drug delivery (IGDD), including real-time image guidance, monitoring, quantitative in vivo characterizations and validation of delivery and response. It will support research in development of integrated imaging-based systems for delivery of drugs or biologics in cancer and other diseases, quantitative imaging assays of drug delivery, and early intervention. **Next deadline is November 22, 2017 with subsequent deadlines of June 21, 2018 and November 22, 2018.**

**2018**

**National Cancer Institute (NCI)/NIH/DHHS Cancer-Related Behavioral Research Through Integrating Existing Data R01 PAR-16-256 & R21 PAR-16-255** seek to integrate two or more independent data sets to answer novel cancer control and prevention questions. Research should apply Integrative Data Analysis (IDA) methods to existing data sources that study behavioral risk factors for cancer, including tobacco use, sedentary behavior, poor weight management, and lack of medical adherence to screening and vaccine uptake. **Application Deadlines are February 7, 2018 for R21 and February 15, 2018 for R21**, with subsequent deadlines through June 2019.

**CONTINUOUS SUBMISSION**

**McDonnell (James S.) Foundation** offers **Collaborative Activity Awards** to initiate interdisciplinary discussions on problems or issues, to help launch interdisciplinary research networks, or to fund communities of researchers/practitioners dedicated to developing new methods, tools, and applications of basic research to applied problems for program areas including **Mathematical & Complex Systems Approaches for Brain Cancer. There are no deadlines for this grant type** and award budgets for collaborative activities will vary greatly depending on the scope of the proposed problem or project.

**American Association for Cancer Research (AACR)** offers **Scholar-in-Training Awards** providing financial support for early career scientists to travel to attend AACR conferences and meetings. **Deadlines vary by individual conferences.**